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(www.retroembrace.com). Data from the EMBRACE and 
retroEMBRACE studies show significant correlation between 
dose and outcome for both local control and morbidity 
(bladder, rectum, bowel, vagina).  
While there is currently not international consensus on dose 
planning aims and dose prescription in cervix cancer, the 
dose effect data from the EMBRACE and retroEMBRACE 
studies will change this situation. The upcoming evidence can 
be used to recommend certain dose planning aims and dose 
prescription levels. A new study (EMBRACE II) will for the first 
time implement a prospective dose prescription protocol for 
both target and organs at risk based on clinical outcome data 
from EMBRACE and retroEMBRACE. EMBRACE II will be 
initiated in 2015. 
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Image guided adaptive brachytherapy (IGABT) as part of 
combined radiochemotherapy for locally advanced cervical 
cancer is associated with improved rates of local control with 
simultaneous decrease in morbidity compared to use of 
standard brachytherapy plans in several institutional series.  
Besides tumor control and morbidity, health related quality 
of life (HR-QoL) including patient reported symptoms can 
provide additional important information to evaluate 
treatment efficacy. While clinician-assessed morbidity scales 
are objectively defined, patient reported symptoms provide a 
subjective evaluation without clinical interpretation. Several 
studies have pointed out that there can be considerable 
underreporting of morbidity when patient reported symptoms 
are taken into account, especially for low grade morbidity.  
Comparison of HR-QoL results with age matched normal 
population data can help to point out which symptoms or 
issues are most prevalent during further follow-up after 
treatment. In addition these results can provide patients with 
more detailed information on what to expect during follow-
up.  
Most HR-QoL studies in patients with cervical cancer report 
on a cross-sectional cohort, are not prospective, and have 
included patients with different treatments and 
gynaecological malignancies. Despite these limitations, in 
general radiochemotherapy for locally advanced cervical 
cancer has found to have a considerable impact on HR-QoL 
and patient reported symptoms. During treatment patients 
report more symptoms of fatigue, nausea, appetite loss, 
diarrhea, pain and insomnia, affecting global health status 
and emotional, social and role functioning,although part of 
these symptoms recover over time. Most studies with longer 
follow-up after treatment still find impairments in 
functioning compared to the general population. And some of 
the symptoms may persist years after treatment, like 
diarrhea, urinary frequency and leaking of urine. In addition, 
survivorship studies indicate that sexual symptoms are 
prevalent and sexual functioning is frequently impaired and a 
major source of distress. 
The EMBRACE study (www.embracestudy.dk) investigated the 
introduction of IGABT in a multicentre setting and included 
prospective HR-QoL assessment with EORTC quality of life 
questionnaires. This trial started in 2008 and has included 
over 1200 patients. In an interim EMBRACE report, a 
comparison between CTCAE morbidity and EORTC patient 
reported symptoms confirmed that there was considerable 
underestimation between both endpoints.  
Preliminary EMBRACE HR-QoL results of this study including a 
comparison with age matched norm population data will be 
presented.  
In conclusion, HR-QoL outcomes provide useful additional 
information besides tumor control and clinician-assessed 
morbidity. These outcomes provide useful information when 
counselling patients on what to expect regarding functioning 
and symptoms. Patient reported HR-QoL and symptom 
endpoints can play and important role in future research in 
order to to optimize the therapeutic window, to decrease 
most prevalent symptoms and to increase patient functioning 
and HR-QoL during follow-up.  
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Purpose/Objective: To identify prognostic factors for local 
control in patients treated for locally advanced cervical 
cancer with image guided adaptive brachytherapy, and 
analyse their potential impact on planning aims. 
Materials and Methods: Patients treated with curative intent 
by a combination of external beam radiotherapy and pulsed-
dose rate brachytherapy were selected. Local failure was 
defined as any relapse in the cervix, vagina, parametria, or 
uterus during follow-up. Prognostic factors were selected 
based on log rank tests and then analyzed with a Cox model. 
Dose/effect correlations were performed using the Probit 
model. 
Results: Two hundred and twenty-five patients treated from 
2006 to 2011 were included. According to the FIGO 
classification, 29% were stage IB, 58% stage II, 10% stage III, 
and 3% stage IVA; 95% received concomitant chemotherapy. 
Thirty patients were considered having incomplete response 
or local failure. Among the selected parameters, D90 for HR-
CTV, D90 for IR-CTV, the overall treatment time, the TRAK, 
and the HR-CTV volume appeared significantly correlated 
with local control in univariate analysis. In multivariate 
analysis, overall treatment time > 55 days and HR-CTV 
volume > 30 cm3 appeared independent.  
The Probit analysis showed significant correlations between 
the D90 for both CTVs, and the probability of achieving local 
control (p=0.008 and 0.024). The thresholds to reach to 
warrant a probability of 90% of local control were 85 Gy to 
